Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Thimble Point Acquisition Corp. | 14,264,640 | reported | 18 Aug 2022 | tx 10+18,631,771−400,000 |
| Q32 Bio Inc. | 4,834,484 | reported | 14 Dec 2020 | tx 9+5,392,037−5,921,719 |
| Vor Biopharma Inc. | 4,595,089 | reported | 16 Nov 2021 | tx 2−330,706 |
| Enliven Therapeutics, Inc. | 4,470,968 | reported | 24 Aug 2023 | tx 5+5,826,042−440,000 |
| Camp4 Therapeutics Corp | 2,941,176 | reported | 11 Sept 2025 | tx 9+5,878,091−22,642,752 |
| Rallybio Corp | 2,378,969 | reported | 07 Mar 2023 | tx 1−100,000 |
| 5:01 Acquisition Corp. | 1,944,068 | reported | 30 Nov 2020 | tx 5+365,126−355,932 |
| Entrada Therapeutics, Inc. | 1,100,248 | reported | 01 Jul 2025 | tx 17+4,077,224−27,818,376 |
| scPharmaceuticals Inc. | 578,034 | reported | 26 May 2020 | tx 1+578,034 |
| Cabaletta Bio, Inc. | 417,629 | reported | 10 Dec 2020 | tx 6+3,669,266−5,120,083 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 06 Feb 2026 | GRANT_AWARD | Skye Bioscience, Inc. | 35,000 | 0.00 USD | deriv |
| 11 Sept 2025 | GRANT_AWARD | Camp4 Therapeutics Corp | 2,941,176 | 1.53 USD | |
| 22 Aug 2025 | SALE | Skye Bioscience, Inc. | 6,470 | 3.42 USD | |
| 22 Aug 2025 | SALE | Skye Bioscience, Inc. | 163,979 | 3.42 USD | |
| 21 Aug 2025 | SALE | Skye Bioscience, Inc. | 58,642 | 3.57 USD | |
| 21 Aug 2025 | SALE | Skye Bioscience, Inc. | 2,314 | 3.57 USD | |
| 01 Jul 2025 | SALE | Entrada Therapeutics, Inc. | 6,422 | 7.12 USD | |
| 01 Jul 2025 | SALE | Entrada Therapeutics, Inc. | 18,578 | 7.12 USD | |
| 27 Jun 2025 | SALE | Entrada Therapeutics, Inc. | 55,735 | 6.91 USD | |
| 27 Jun 2025 | SALE | Entrada Therapeutics, Inc. | 19,265 | 6.91 USD | |
| 30 Jun 2025 | SALE | Entrada Therapeutics, Inc. | 18,578 | 6.81 USD | |
| 30 Jun 2025 | SALE | Entrada Therapeutics, Inc. | 6,422 | 6.81 USD | |
| 25 Jun 2025 | GRANT_AWARD | Camp4 Therapeutics Corp | 9,000 | 0.00 USD | deriv |
| 24 Feb 2025 | GRANT_AWARD | Skye Bioscience, Inc. | 35,000 | 0.00 USD | deriv |
| 28 Oct 2024 | GRANT_AWARD | Skye Bioscience, Inc. | 70,000 | 0.00 USD | deriv |
| 15 Oct 2024 | CONVERSION | Camp4 Therapeutics Corp | 378,463 | — | |
| 15 Oct 2024 | CONVERSION | Camp4 Therapeutics Corp | 302,770 | — | |
| 15 Oct 2024 | PURCHASE | Camp4 Therapeutics Corp | 909,090 | 11.00 USD | first after silence |
| 15 Oct 2024 | CONVERSION | Camp4 Therapeutics Corp | 1,337,592 | — | |
| 15 Oct 2024 | CONVERSION | Camp4 Therapeutics Corp | 4,244,770 | — | deriv |
| 15 Oct 2024 | CONVERSION | Camp4 Therapeutics Corp | 3,395,816 | — | deriv |
| 15 Oct 2024 | CONVERSION | Camp4 Therapeutics Corp | 15,002,166 | — | deriv |
| 13 Sept 2024 | SALE | Skye Bioscience, Inc. | 79 | 6.06 USD | |
| 13 Sept 2024 | SALE | Skye Bioscience, Inc. | 2,000 | 6.06 USD | |
| 13 Sept 2024 | SALE | Skye Bioscience, Inc. | 11,758 | 6.06 USD |
2 purchases reported after at least 12 months of silence — most recent on 15 Oct 2024.